|
Prevalence of potential drug-drug interactions
with ritonavir-containing COVID-19 therapies
|
|
|
Presented at the 24th Annual MAD-ID Meeting; Orlando, FL, USA; May 18-21, 2022
Amy Puenpatom1; Marissa Grifasi Williams1; Yan Song2; Denise Yi2; Jessie Wang2; Miley Gu2; Chujun He2; Richard Berman2; and Ebuwa Igho-Osagie1
1Merck & Co., Inc., Rahway, NJ, USA; 2Analysis Group, Inc., Boston, MA, USA
![0525221](../images/052522/052422-2/0525221.gif)
![0525222](../images/052522/052422-2/0525222.gif)
![0525223](../images/052522/052422-2/0525223.gif)
![0525224](../images/052522/052422-2/0525224.gif)
![0525225](../images/052522/052422-2/0525225.gif)
![0525226](../images/052522/052422-2/0525226.gif)
![0525227](../images/052522/052422-2/0525227.gif)
|
|
|
|
|
|
|